Mortality from Klebsiella pneumoniae Bloodstream Infection in the Era of Novel β-Lactam/β-Lactamase Inhibitors

Carbapenem resistance in K. pneumoniae might no longer be a risk factor for mortality in the age of ceftazidime/avibactam.

Bloodstream infection (BSI) caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp) has historically been associated with higher mortality than BSI caused by carbapenem-susceptible K. pneumoniae (CS-Kp). As this difference could not be explained by comorbidities, illness severity, time to antibiotic initiation, or pathogen virulence, the shortcomings of polymyxin-based regimens were deemed responsible. What effect does carbapenem resistance have on mortality from K. pneumoniae BSI in the era of novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations?

In an Italian, retrospective, multicenter study involving 427 hospital patients (median age, 67) between January and August 2020, 75% of participants had CS-Kp and 25% had CR-Kp, yieldin…

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases